

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lancot et al.	Confirmation No.:	7406
Serial No.:	09/641,931	Art Unit:	1639
Filing Date:	August 18, 2000	Examiner:	Jon D. Epperson
Patent No.:	6,830,885	Customer No.:	21559
Issued:	December 14, 2004		
Title:	NUCLEIC ACID MOLECULE, METHOD AND KIT FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE		

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 C.F.R. § 3.73(b), Enobia Pharma Inc., a corporation, certifies that it is the assignee of 100% of the right, title, and interest in the patent application identified above by virtue of a chain of title from the inventors of the application to the current assignee, as shown below.

1. From the inventors of the application to Phénogène Thérapeutiques Inc., as recorded in the Patent and Trademark Office at Reel 011032, Frame 0476, on August 18, 2000.

2. From Phénogène Thérapeutiques Inc. to T2C2/Bio 2000, Société en Commandite, as recorded in the Patent and Trademark Office at Reel 021785, Frame 0438, on November 5, 2008.

3. From T2C2/Bio 2000, Société en Commandite to Biomep Inc., as recorded in the Patent and Trademark Office at Reel 021785, Frame 0472, on November 5, 2008.

4. A Change of Name from Biomep Inc. to Enobia Pharma Inc., as recorded in the Patent and Trademark Office at Reel 021785, Frame 0521, on November 5, 2008.

The undersigned has reviewed all the documents in the chain of title of the application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned, whose title is supplied below, is empowered to act on behalf of the assignee.

The undersigned, acting on behalf of the assignee, hereby revokes all powers of attorney previously granted in the application and appoints the attorneys and/or agents of Clark & Elbing LLP, associated with customer number **21559**, with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.


All correspondence regarding the application should be sent to the address associated with customer number **21559**.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the

validity of the application or any patents issued thereon.

Respectfully submitted,

Date: October 29/2010


Philippe Crine, Ph.D.
Vice President & Chief Scientific Officer
Enobia Pharma Inc.